
|Articles|September 1, 2002
Call made for anti-inflammatory systemic Tx
Berlin - New therapeutic modalities are needed for treating thesubstantial population of acne patients with marked inflammatory diseaseand scarring. Available data indicate compounds with selective anti-inflammatoryactivity may help fill that niche, Christos C. Zouboulis, M.D., said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
5











